论文部分内容阅读
目的观察羟基喜树硷联合顺铂化疗方案治疗晚期非小细胞肺癌的临床疗效和毒副反应。方法采用羟基喜树硷10 m g/m2静注,第1~5天,顺铂20 m g/m2,第1~3天。结果完全缓解2例,部分缓解12例,总有效率为42.4%,中位生存期11.5个月,0.5、1、2年生存率分别为66.7%、8.5%、33.3%。主要毒副反应是骨髓抑制和消化道反应,但均可耐受。结论羟基喜树硷联合化疗治疗晚期非小细胞肺癌疗效确切,副作用可耐受,该药是治疗非小细胞肺癌较为有效的药物,值得在临床推广和应用。
Objective To observe the clinical efficacy and toxicity of hydroxycamptothecin combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Hydroxycamptothecin 10 m g / m2 intravenous injection, the first 5 days, cisplatin 20 m g / m2, 1 to 3 days. The results of complete remission in 2 cases, partial remission in 12 cases, the total effective rate was 42.4%, the median survival of 11.5 months, 0.5, 1, 2-year survival rates were 66.7%, 8.5%, 33.3%. The main toxicity is myelosuppression and gastrointestinal reactions, but can be tolerated. Conclusion Hydroxycamptothecin combined with chemotherapy for the treatment of advanced non-small cell lung cancer has definite curative effect and tolerable side effects. It is a more effective drug for the treatment of non-small cell lung cancer and is worthy of clinical application.